ADIPOQ and type 2 diabetes mellitus: A systematic review and meta-analysis of RCTs on the effect of SGLT2i on the blood adiponectin level in patients with type 2 diabetes showed that treatment with SGLT2i contributed to increased circulating adiponectin levels (+0.30; 95%CI 0.22 to 0.38) [8].